Conditions: Alzheimer's Disease
Keywords: Isotretinoin Alzheimer's disease Dementia Retinoid
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 3
Healthy volunteers: no

Brief summary:
This is an open label study of isotretinoin, a medication which is FDA approved for treatment of other conditions to determine initial safety in Alzheimer's disease.

Detailed description:
Retinoids have some relevant characteristics that could be considered useful in treating AlZheimer's disease. These include anti-inflammatory properties, possible anti-amyloid formation proeprties and inhibition of cell cycle properties

Arms:
arm 1: All participants will receive Isotretinoin for 24 weeks

Interventions: intervention 1: Isotretinoin
Intervention descriptions: intervention 1: Isotretinoin 0.5 mg per kilogram body weight (rounded to nearest 10 mg) per day for 24 weeks

Protocol document: